

FIGURE 1A




FIGURE 1B




FIGURE 1C




Figure 2A




Figure 2B




FIGURE 3A




FIGURE 3B




FIGURE 3C




FIGURE 4A




FIGURE 4B




FIGURE 4C




FIGURE 5




Figure 6




Figure 7A




Figure 7B




Figure 8




Figure 9A






Figure 9B








Figure 11A




Figure 11B




Figure 11C




Figure 11D




Figure 12A




Figure 12B





Figure 13A




Figure 13B




Figure 13C
Xcellgene RTCA killing assay (E:T ratio=3:1)




Figure 14




Figure 15A




Figure 15B




Figure 16A




Figure 16B




Figure 17A




Figure 17B




Figure 18A




Figure 18B




Figure 19A

TeIL-15-REP TIL




Figure 19B




Figure 20A

TeIL-15/TeIL-21 REP-TIL




Figure 20B




Figure 21A




Figure 21B




Figure 22A




Figure 22B




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 31




Figure 32




Figure 33




Figure 34




Figure 35A




Figure 35B




Figure 36A




Figure 36B




Figure 37




Figure 38




Figure 39




Figure 40




Figure 41




Figure 42




Figure 42A




Figure 42B

Figure 43




Figure 44





Figure 45






Figure 47




Figure 48




Figure 49




Figure 50




Figure 51




Figure 52




Figure 53




Figure 54




Figure 55




Figure 56




Figure 57




Figure 58




Figure 59




Figure 60




FIGURE 60B




FIGURE 60A

Figure 61




Figure 62




Figure 63A




Figure 63B

% TeIL15⁺ in CD4⁺ T cells




Figure 65




Figure 66




Figure 67




Figure 68




Figure 69




Figure 70




Figure 71




Figure 72




Figure 73




Figure 74






Figure 75



Sequence: Ba-EV TR_pCMV-3Tag-4a.dna (Circular / 5784 bp)
Enzymes: Unique 6+ Cutters (41 of 667 total)
Features: 14 total

Unique Cutters **Bold**

FIGURE 76



Sequence: Kanamycin_plenti-NFAT-TeIL12-EF1a-TeIL15.dna (Circular / 11,032 bp)
Enzymes: Unique 6+ Cutters (41 of 667 total)
Features: 36 total

Unique Cutters **Bold**

FIGURE 77




Figure 78




Figure 79




Figure 80




FIGURE 81



Figure 82

Process 2A: about 22 days from Steps A - E

1. STEP A

Obtain Patient Tumor Sample

2. STEP B

Fragmentation and First Expansion

3 days to 14 days

3. STEP C

First Expansion to Second Expansion Transition

No Storage and Closed System

4. STEP D

Second Expansion

IL-2, OKT-3, and antigen-presenting feeder cells

Closed System

5. STEP E

Harvest TILs from Step D

Closed System

6. STEP F

Final Formulation and/or Transfer to Infusion Bag

(optionally cryopreserve)




Figure 2B

Figure 83B




Figure 83C

